The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Risankizumab Effective Against Refractory Psoriatic Arthritis

Risankizumab Effective Against Refractory Psoriatic Arthritis

January 22, 2022 • By Matthew Phelan

  • Tweet
  • Email
Print-Friendly Version / Save PDF

At the 24-week mark, 57.3% of patients receiving risankizumab achieved ACR20, compared with 33.5% of patients on placebo (P<0.001).

You Might Also Like
  • Risankizumab May Improve Symptoms of PsA
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis

Eight of the study’s secondary endpoints also showed significant improvement, including skin (PASI 90) and nail (mNAPSI and PGA-F) psoriasis endpoints, minimal disease activity, and resolution of enthesitis and dactylitis (P<0.001).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For patients with greater than 3% of their body surface area impacted by psoriasis at baseline, a significantly greater proportion of patients achieved PASI 90 alleviation of symptoms with risankizumab versus placebo (52.3% vs. 9.9%; P<0.001).

Risankizumab also produces significant improvements in ACR50 (33.4% vs. 11.3%) and ARC70 (15.3% vs. 4.7%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Kristian Reich, who studies inflammatory skin diseases at University Medical Center Hamburg-Eppendorf, in Germany, and was not involved in the study, says ACR50 would be a preferable treatment goal over ARC20. Risankizumab is currently “miles away” from that goal, he tells Reuters Health by email.

“In principle, the paper shows disappointing results clearly indicating that TNF and IL-17 inhibitors but not IL-12/23 or IL-23 inhibitors are the main therapies in PsA,” says Dr. Reich.

“We want to overcome the toxicity of cDMARDs by using more powerful and safer biologics and not having to combine biologics with cDMARDS because alone they do not work well enough,” he says.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Citing a full year of data (52 weeks) from a second KEEPsAKE trial, however, Dr. Kristensen noted that risankizumab’s mode of action – which is immune-modulating, rather than immune-effector inhibiting—may lead to further improved symptoms with longer use.

“I really believe that the interesting data is long-term data with this mode of action,” that is, p19 inhibition, Dr. Kristensen says. “Risankizumab responds gradually over time instead of climbing to a rapid but clamped response.”

The biopharmaceutical company AbbVie, which manufactures and markets risankizumab under the trade name Skyrizi, funded and participated in the design of the two KEEPsAKE trials. Dr. Kristensen has financial ties to the company.


Reference
  1. Kristensen LE, Keiserman M, Papp K, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. 2022 Feb;81(2):225–231. Epub 2021 Dec 15.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: PsA, PsA Resource Center, Psoriatic Arthritis, refractory PsA, risankizumab

You Might Also Like:
  • Risankizumab May Improve Symptoms of PsA
  • Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis
  • Apremilast Effective for Psoriatic Arthritis
  • Secukinumab Effective Across the Spectrum of Psoriatic Arthritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)